Anti-IL5R and anti-IL4Rα strategy in patients with severe allergic asthma: clinical observations

With the narrow action of immunobiological drugs, it is necessary to understand the pathogenetic mechanisms of severe asthma (SA) in a particular patient.

The aim of the work was to demonstrate the importance of determining the endotype and phenotype of SA to select a targeted drug using the example of cases of anti-IL5R treatment failure in patients with allergic SA (ASA). Patients (n = 2) with ASA onset in childhood, identified causative allergens, and high eosinophilia before the start of targeted therapy are presented. The use of the anti-IL5 drug benralizumab in such cases is permitted by the Guidelines for Biological Therapy (The European Academy of Allergy and Clinical Immunology – EAACI, 2020), but the therapy was ineffective. The patients were switched to the anti-IL4R drug dupilumab, which indirectly blocks IgE production, with a positive outcome.

Conclusion. The considered cases of ASA demonstrate the necessity of determining the endotype and phenotype of SA to select the targeted drug. The inefficiency of the anti-IL5R drug in patients with ASA is shown, despite the pronounced initial blood eosinophilia. In case of Th2-mediated eosinophilia in ASA, preference should be given to anti-IgE or anti-IL4R drugs.

1. Agache I.O. From phenotypes to endotypes to asthma treatment. Curr. Opin. Allergy Clin. Immunol. 2013; 13 (3): 249–256. DOI: 10.1097/ACI.0b013e32836093dd.

2. Chung K.F. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr. Opin. Pulm. Med. 2018; 24 (1): 4–10. DOI: 10.1097/MCP.0000000000000434.

3. Ozdemir C., Kucuksezer U.C., Akdis M. et al. The concepts of asthma endotypes and phenotypes to guide current and novel treatment strategies. Expert Rev. Respir Med. 2018; 12 (9): 733–743. DOI: 10.1080/17476348.2018.1505507.

4. Moore W.C., Meyers D.A., Wenzel S.E. et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 2010; 181 (4): 315–323. DOI: 10.1164/rccm.200906-0896OC.

5. Haldar P., Pavord I.D., Shaw D.E. et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 2008; 178 (3): 218–224. DOI: 10.1164/rccm.200711-1754OC.

6. Lefaudeux D., De Meulder B., Loza M.J. et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J. Allergy Clin. Immunol. 2017; 139 (6): 1797–1807. DOI: 10.1016/j.jaci.2016.08.048.

7. Simpson J.L., Scott R., Boyle M.J., Gibson P.G. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006; 11 (1): 54–61. DOI: 10.1111/j.1440-1843.2006.00784.x.

8. Yan X., Chu J.H., Gomez J. et al. Noninvasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma. Am. J. Respir. Crit. Care Med. 2015; 191 (10): 1116–1125. DOI: 10.1164/rccm.201408-1440OC.

9. Denton E., Price D.B., Tran T.N. et al. Cluster analysis of inflammatory biomarker expression in the International severe asthma registry. J. Allergy Clin. Immunol. Pract. 2021; 9 (7): 2680–2688.e7. DOI: 10.1016/j.jaip.2021.02.059.

10. Kaur R., Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J. Allergy Clin. Immunol. 2019; 144 (1): 1–12. DOI: 10.1016/j.jaci.2019.05.031.

11. Nenasheva N.M., Kurbacheva O.M., Avdeev S.N. et al. [Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype]. Pul'monologiya. 2020; 30 (2): 227-244. DOI: 10.18093/0869-0189-2020-30-2-227-244 (in Russian).

12. Naumova V.V., Beltyukov E.K., Kovtun O.P. et al. [Clinical and allergological characteristics of patients with severe bronchial asthma in the regional registry and phenotyping principles for the targeted therapy choice]. Meditsinskiy sovet. 2024; (9): 47–61. DOI: 10.21518/ms2024-177 (in Russian).

13. Agache I., Akdis C.A., Akdis M. et al. EAACI biologicals guidelines-recommendations for severe asthma. Allergy. 2021; 76 (1): 14–44. DOI: 10.1111/all.14425.

14. Chipps B.E., Newbold P., Hirsch I. et al. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann. Allergy Asthma Immunol. 2018; 120 (5): 504–511.e4. DOI: 10.1016/j.anai.2018.01.030.

15. Bleecker E.R., FitzGerald J.M., Chanez P. et al. SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–2127. DOI: 10.1016/S0140-6736(16)31324-1.

16. FitzGerald J.M., Bleecker E.R., Nair P. et al. CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–2141. DOI: 10.1016/S0140-6736(16)31322-8.

17. Naumova V., Beltyukov E., Niespodziana K. et al. Cumulative IgE-levels specific for respiratory allergens as biomarker to predict efficacy of anti-IgE-based treatment of severe asthma. Front. Immunol. 2022; 13: 941492. DOI: 10.3389/fimmu.2022.941492.

18. Abe Y., Suga Y., Fukushima K. et al. Advances and challenges of antibody therapeutics for severe bronchial asthma. Int. J. Mol. Scie. 2022; 23 (1): 83. DOI: 10.3390/ijms23010083.